Bio­phar­ma has hyped AI for years. But as the first tri­als get un­der­way, ex­perts try to man­age ex­pec­ta­tions

If you’re at all fa­mil­iar with the biotech space, you’ve prob­a­bly heard of the promis­es of ar­ti­fi­cial in­tel­li­gence and ma­chine learn­ing.

These promis­es have been tan­ta­liz­ing. AI and ML can, pro­po­nents claim, help re­searchers speed along the ar­du­ous and ex­pen­sive drug de­vel­op­ment process. By at­tempt­ing to uti­lize al­go­rithms and com­put­ing pow­er so dy­nam­ic as to es­sen­tial­ly elim­i­nate me­nial tasks and tri­al and er­ror al­to­geth­er, the tech­nol­o­gy comes with big ex­pec­ta­tions liken­ing it to a new in­dus­tri­al rev­o­lu­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER